Founded by a team of urologists, Rivermark Medical is dedicated to developing innovative urology devices with a core mission to provide minimally-invasive treatments for Benign Prostatic Hyperplasia (BPH). Their flagship product, the FloStent™ System, is designed to rapidly restore urinary function, allowing patients to return to their daily lives quickly. This device is administered in-office using a standard cystoscope, making it a cost-effective and patient-centered solution that is also reversible.
Rivermark Medical has garnered attention from notable investors and medical professionals in the field of urology. The company's achievements include the successful development and deployment of the FloStent™ System, which has been recognized for its efficacy and minimal side effects. Rivermark Medical's impact lies in its ability to offer a reliable first-line therapy for BPH, significantly improving the quality of life for patients while reducing the need for more invasive surgical procedures.
